Financial Support: The American Migraine Prevalence and Prevention (AMPP) Study was funded through a research grant to the National Headache Foundation from McNeil-Janssen Scientific Affairs LLC, Raritan, NJ. The AMPP database was donated by McNeil-Janssen Scientific Affairs LLC to the National Headache Foundation for use in various projects. Additional funding and support for this manuscript was provided through a grant to the National Headache Foundation by ENDO Pharmaceuticals, Chadds Ford, PA.
Sex Differences in the Prevalence, Symptoms, and Associated Features of Migraine, Probable Migraine and Other Severe Headache: Results of the American Migraine Prevalence and Prevention (AMPP) Study
Article first published online: 28 JUN 2013
© 2013 American Headache Society
Headache: The Journal of Head and Face Pain
Volume 53, Issue 8, pages 1278–1299, September 2013
How to Cite
Buse, D. C., Loder, E. W., Gorman, J. A., Stewart, W. F., Reed, M. L., Fanning, K. M., Serrano, D. and Lipton, R. B. (2013), Sex Differences in the Prevalence, Symptoms, and Associated Features of Migraine, Probable Migraine and Other Severe Headache: Results of the American Migraine Prevalence and Prevention (AMPP) Study. Headache: The Journal of Head and Face Pain, 53: 1278–1299. doi: 10.1111/head.12150
Conflict of Interest: Dawn C. Buse, PhD, has received grant support and honoraria from Allergan Pharmaceuticals, MAP Pharmaceuticals, Novartis and NuPathe. Elizabeth W. Loder, MD, MPH, reports receiving salary support from the British Medical Journal in exchange for services as a clinical editor. Jennifer A. Gorman, MS, has nothing to disclose. Walter F. Stewart, PhD, received grants from Allergan Pharmaceuticals, Endo Pharmaceuticals, GlaxoSmithKline, Minster, Merck, Inc., Neuralieve, Novartis, OrthoMcNeil, Pfizer, the National Headache Foundation, and the National Institutes of Health. Michael L. Reed, PhD, has received funding for research and data analysis from Allergan Inc., CoLucid, Endo Pharmaceuticals, GlaxoSmithKline, MAP Pharmaceuticals, Merck, Novartis, NuPathe, Ortho-McNeil, and the National Headache Foundation. Kristina M. Fanning, PhD, has received research support from Allergan Inc., CoLucid, Endo Pharmaceuticals, GlaxoSmithKline, MAP Pharmaceuticals, Merck & Co., Inc., NuPathe, Novartis, Ortho-McNeil, and the National Headache Foundation. Daniel Serrano, PhD, has received research support from Allergan Inc., CoLucid, Endo Pharmaceuticals, GlaxoSmithKline, MAP Pharmaceuticals, Merck & Co., Inc., NuPathe, Novartis, Ortho-McNeil, and the National Headache Foundation. Richard B. Lipton, MD, receives research support from the NIH [PO1 AG03949 (Program Director, Project and Core Leader), RO1AG025119 (Investigator), RO1AG022374-06A2 (Investigator), RO1AG034119 (Investigator), RO1AG12101 (Investigator), K23AG030857 (Mentor), K23NS05140901A1 (Mentor), and K23NS47256 (Mentor)], the National Headache Foundation, and the Migraine Research Fund; serves on the editorial board of Neurology, has reviewed for the NIA and NINDS, holds stock options in eNeura Therapeutics; serves as consultant, advisory board member, or has received honoraria from: Allergan, American Headache Society, Autonomic Technologies, Boehringer-Ingelheim Pharmaceuticals, Boston Scientific, Bristol Myers Squibb, Cognimed, Colucid, Eli Lilly, ENDO, eNeura Therapeutics, GlaxoSmithKline, Merck, Novartis, NuPathe, Pfizer, and Vedanta.
- Issue published online: 10 SEP 2013
- Article first published online: 28 JUN 2013
- Accepted manuscript online: 16 MAY 2013 07:01AM EST
- Manuscript Accepted: 11 MAY 2013
- McNeil-Janssen Scientific Affairs LLC
- ENDO Pharmaceuticals
- Allergan Pharmaceuticals
- MAP Pharmaceuticals
- British Medical Journal
- Merck, Inc.
- National Headache Foundation
- National Institutes of Health. Grant Numbers: PO1 AG03949, RO1AG025119, RO1AG022374-06A2, RO1AG034119, RO1AG12101, K23AG030857, K23NS05140901A1, K23NS47256
- Migraine Research Fund
- American Headache Society
- Autonomic Technologies
- Boehringer-Ingelheim Pharmaceuticals
- Boston Scientific
- Bristol Myers Squibb
- Eli Lilly
- eNeura Therapeutics
Options for accessing this content:
- If you have access to this content through a society membership, please first log in to your society website.
- If you would like institutional access to this content, please recommend the title to your librarian.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
- New Users: Please register, then proceed to purchase the article.
Type your institution's name in the box below. If your institution is a Wiley customer, it will appear in the list of suggested institutions and you will be able to log in to access content. Some users may also log in directly via OpenAthens.
Please note that there are currently a number of duplicate entries in the list of institutions. We are actively working on fixing this issue and apologize for any inconvenience caused.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!
Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.